Increasing HPV vaccination rates among young adults in Texas
Promoting HPV Vaccination Among Young Adults in Texas
This study is trying different ways to encourage young adults in Texas to get the HPV vaccine and see which method helps them get vaccinated more effectively.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1200 (estimated) |
| Ages | 18 Years to 26 Years |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT05057312 on ClinicalTrials.gov |
What this trial studies
This clinical trial focuses on improving the HPV vaccination rates among young adults aged 18-26 in Texas. It aims to assess the effectiveness of various informational interventions, including standard CDC information, video narratives, and written narratives, combined with enhanced access to vaccination services. Participants are randomized into six groups to evaluate the impact of these different approaches on vaccination initiation and completion rates. The study will also explore individual differences and the mechanisms behind the intervention's efficacy through mixed methods. Follow-up assessments will occur at 3 and 9 months post-intervention.
Who should consider this trial
Good fit: Ideal candidates for this study are young adults aged 18-26 who have not yet received any HPV vaccine injections.
Not a fit: Patients who have already been vaccinated against HPV or are outside the age range of 18-26 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly increase HPV vaccination rates among young adults, leading to reduced incidence of HPV-related diseases.
How similar studies have performed: Other studies have shown success in using informational interventions to improve vaccination rates, making this approach promising yet still relevant for further exploration.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-26 years. This criterion is based on the CDC recommendation of vaccination up to 26 years of age and the fact that individuals 18 years and older can consent by themselves for on-site vaccination * Ability to read and understand English * Self-identification as not yet having received any HPV vaccine injections. Self-identification is justified because it is safe to be vaccinated again, which could happen if a previously vaccinated person forgets their vaccination. Furthermore, in a person previously vaccinated with an older version of the vaccine, which targeted fewer HPV types, receiving the newer version would be advantageous and not cause any harm. Alternatives to self-identification, such as obtaining medical records from doctors' offices, would be very challenging for young adults, especially for those who do not remember when and where they might have received vaccination * Access to a smart phone, tablet or computer that is connected to the internet * Current enrollment in one of the participating schools with an anticipated continuous enrollment of at least 9 months Exclusion Criteria: * Being pregnant * Having a life-threatening allergy to any component of the HPV vaccine
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Qian Lu, MD,PHD — M.D. Anderson Cancer Center
- Study coordinator: Qian Lu, MD,PHD
- Email: qlu@mdanderson.org
- Phone: (713) 745-8324
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.